Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RMAT Designation, Gene Therapies Highlight 2017 CBER Transformation

Executive Summary

CBER Director Peter Marks says the center implemented a lot in a short amount of time for the RMAT pathway.


Related Content

Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
Panel Of Former US FDA Commissioners Make Renewed Call For Independent Agency
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
Gene Therapy Manufacturing Remains Large Hurdle For Development, US FDA's CBER Director Says
Keeping Track: A Little Bit Of (Nearly) Everything
Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss
Regenerative Medicine Clinical Trials: US FDA Supports Studies Comparing Multiple Agents
Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval
How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss
US FDA First's RMAT Designation: Humacyte Got A 'Quick Response'


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts